Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $30.00 price target on the stock.
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) had its "outperform" rating re-affirmed by analysts at Lifesci Capital.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]